Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 5—May 2007

Dispatch

Tuberculosis Drug Resistance and HIV Infection, the Netherlands

Catharina Hendrika Haar*†, Frank G.J. Cobelens*‡Comments to Author , Nico A. Kalisvaart*, Jan J. van der Have†, Paul J.H.J. van Gerven*, and Dick van Soolingen§
Author affiliations: *KNCV Tuberculosis Foundation, The Hague, the Netherlands; †Municipal Health Service, Groningen, the Netherlands; ‡Academic Medial Centre, Amsterdam, the Netherlands; §National Institute of Public Health and the Environment, Bilthoven, the Netherlands;

Main Article

Table 2

Prevalence of secondary drug resistance among previously treated tuberculosis patients, the Netherlands, 1993–2001*


No. HIV negative (%) 
(n = 294)
No. HIV positive (%)
(n = 21)
Fully susceptible 232 (78.9) 15 (71.4)
Resistant to 1 drug:
  Isoniazid
  Rifampin
  Streptomycin
34 (11.9)
20 (6.8)
0
14 (4.8)
4 (19.0)
2 (9.5)
2 (9.5)
0
Resistant to 2 drugs
17 (5.8)
0
Resistant to 3 drugs
4 (1.4)
0
Resistant to 4 drugs
7 (2.4)
2 (9.5)
Any resistance
62 (21.1)
6 (28.6)
Any resistance to:


  Isoniazid
48 (16.3)
4 (19.0)
  Rifampin
15 (5.1)
4 (19.0)*
  Streptomycin
36 (12.2)
2 (9.5)
  Ethambutol
9 (3.1)
2 (9.5)
Multidrug resistance† 15 (5.1) 2 (9.5)

*Undajusted odds ratio 4.12 (95% confidence interval 1.01–15.67, p = 0.036).
†Resistant to at least isoniazid and rifampin.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO